Medicare spending on each dose of Sanofi Genzyme’s Renvela has been ratcheting up by an annual growth rate of 21.6 percent for roughly the last five years. Nearly the same is true for Sanofi’s Lantus, Merck’s Zetia, and Amgen’s Enbrel — Medicare spending on all of them climbed by an annual rate of more than 18 percent between 2012 and 2016.

Now the Trump administration is calling out the companies behind those increases as part of an effort to tout its updates to the Centers for Medicare and Medicaid Services “drug pricing dashboard” and the data available there. It updated the dashboard Tuesday as part of its broader effort to put forth policies and changes that will help lower drug prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy